Cited by 94T-cell and B-cell ImmunologyImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Costimulation of T Cells

BUGEON, LAURENCE, DALLMAN, MARGARET J.·2000·American Journal of Respiratory and Critical Care Medicine

Abstract

Costimulation is critical to T cell activation. On the antigen-presenting cell the key players are found in the extended family of B7 genes comprising cd80, cd86, B7h/B7RP-1 and B7-H1. cd80 and cd86 encode proteins that bind to CD28 and CTLA4 on T cells. Blocking this pathway with the potent CTLA4-Ig fusion protein shows encouraging potential as a therapeutic agent. While cd80 and cd86 pathways act mainly on naive T cells, B7h/B7RP-1 and B7-H1 seem to exert their effects on antigen-experienced lymphocytes.

Integrity signals

Registry

Crossref · 10.1164/ajrccm.162.supplement_3.15tac5

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CD28 is a co-stimulatory receptor on T cells; engagement by CD80 and CD86 on antigen-presenting cells provides a second signal supporting T-cell activation, survival, proliferation, cytokine production, and differentiation.

    “In classical immunology, CD28 is best known as a co-stimulatory receptor on T cells. Its engagement by the B7-family ligands CD80 and CD86 on antigen-presenting cells provides a second signal that supports T-cell activation, survival, proliferation, cytokine production, and differentiation.”
  • CD80 and CD86 are potent T-cell co-stimulators, and CD28 tunes the quality, duration, and metabolic consequences of immune activation.

    “Early studies in the 1990s established CD80 and CD86 as potent T-cell co-stimulators, while later reviews refined the view of CD28 as a receptor that does not simply “turn on” T cells, but tunes the quality, duration, and metabolic consequences of immune activation [40,41,42].”
  • In Alzheimer's disease and aging, microglia and peripheral myeloid cells may express co-stimulatory ligands, but the ligand-receptor architecture within the plaque microenvironment remains incompletely defined.

    “In Alzheimer’s disease and aging, microglia and peripheral myeloid cells may express co-stimulatory ligands, but the ligand–receptor architecture within the plaque microenvironment remains incompletely defined.”
  • Without CD28 co-stimulation, antigen recognition alone may lead to incomplete activation, tolerance, or anergy.

    “Without this co-stimulatory context, antigen recognition alone may lead to incomplete activation, tolerance, or anergy.”
  • CD80 and CD86 are traditionally expressed by antigen-presenting cells and bind CD28 and CTLA-4 on T cells.

    “CD80 and CD86 are traditionally expressed by antigen-presenting cells and bind CD28 and CTLA-4 on T cells.”

The citation lists haven’t been fetched yet

References 50 · Cited by 94

Authors
BUGEON, L., & DALLMAN, M. J.
Affiliations
Imperial College London (GB)
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2000-10-01
Volume
162
Issue
Supplement_3
Pages
S164-S168
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2155563436
Cited by
94
References
50
Citations by year
2026: 3 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 24 · 2020: 4 · 2019: 4 · 2015: 2 · 2014: 3 · 2013: 7 · 2012: 2
FWCI
0.33
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
T cell costimulation, T cell activation, B7 family, CD80, CD86, PD-L1, CD28, CTLA-4, antigen-presenting cells, naive T cells
MeSH terms
Antigen-Presenting Cells, Genes, MHC Class II, Humans, Lymphocyte Cooperation, Lymphocyte Activation, T-Lymphocyte Subsets

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review